SCHEMBL17628618

SCHEMBL17628618

CCCn1cnc2c(NCc3cccnc3)nc(Cl)nc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 2/20 0.57
ADORA1 P30542 3/20 0.54
TMIGD3 P0DMS9 2/20 0.54
ADORA2A P29274 2/20 0.54
ADORA3 P0DMS8 1/20 0.52
CTSL P07711 3/20 0.52
HDAC1 Q13547 1/20 0.51
PKM P14618 1/20 0.51
RAD52 P43351 1/20 0.51
CDK2 P24941 4/20 0.51
CCNA2 P20248 1/20 0.51
CCNA1 P78396 1/20 0.51
CACNA1B Q00975 1/20 0.51
YTHDC1 Q96MU7 2/20 0.50
CDK9 P50750 2/20 0.50
CTSB P07858 1/20 0.49
CCNK O75909 1/20 0.49
CDK12 Q9NYV4 1/20 0.49
CCNE2 O96020 1/20 0.48
CCNE1 P24864 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6817859 0.88 CDK1 (0.74) CDK1ADORA1TMIGD3ADORA2ACTSL
SCHEMBL17628574 0.87 CDK1 (0.76) CDK1ADORA1ADORA3PKMRAD52
SCHEMBL6152650 0.83 CTSL (0.69) CDK1ADORA1TMIGD3ADORA2ACTSL
SCHEMBL6820865 0.82 PPARG (0.65) ADORA1ADORA2AADORA3
SCHEMBL17628578 0.82 CDK1 (0.65) CDK1ADORA1TMIGD3ADORA2ACTSL
SCHEMBL3859252 0.82 CDK1 (0.78) CDK1CDK2CCNA2CCNA1CDK9
SCHEMBL17628607 0.80 CDK2 (0.81) CDK1CDK2CCNA2CCNA1CACNA1B
SCHEMBL17628604 0.80 CDK2 (0.81) CDK1CDK2CCNA2CCNA1CACNA1B
SCHEMBL6944109 0.80 CCNE2 (0.76) CDK1ADORA1TMIGD3ADORA2ACTSL
SCHEMBL17628580 0.79 TMIGD3 (0.70) CDK1ADORA1TMIGD3ADORA2ACTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752629-B2 Calcium channel agonists University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2020-08-25 US disclosed
US-10752629-B2 Calcium channel agonists University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2020-08-25 US disclosed
US-20190084984-A1 CALCIUM CHANNEL AGONISTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2019-03-21 US disclosed
US-20190084984-A1 CALCIUM CHANNEL AGONISTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2019-03-21 US disclosed
US-10174031-B2 Calcium channel agonists University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2019-01-08 US disclosed
US-10174031-B2 Calcium channel agonists University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2019-01-08 US disclosed
US-20180009810-A1 CALCIUM CHANNEL AGONISTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2018-01-11 US disclosed
US-20180009810-A1 CALCIUM CHANNEL AGONISTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2018-01-11 US disclosed
US-9796714-B2 Calcium channel agonists University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2017-10-24 US disclosed
US-9796714-B2 Calcium channel agonists University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2017-10-24 US disclosed
US-9796714-B2 Calcium channel agonists University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2017-10-24 US disclosed
US-20160090387-A1 CALCIUM CHANNEL AGONISTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2016-03-31 US disclosed
US-20160090387-A1 CALCIUM CHANNEL AGONISTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2016-03-31 US disclosed
US-20160090387-A1 CALCIUM CHANNEL AGONISTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2016-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180009810-A1 CALCIUM CHANNEL AGONISTS CACNA1E, CACNA1C, CACNA1S CDK1 2530/4885ADORA1 381/4885TMIGD3 2058/4885
US-20190084984-A1 CALCIUM CHANNEL AGONISTS CACNA1E, CACNA1C, CACNA1S CDK1 2530/4885ADORA1 381/4885TMIGD3 2058/4885
US-20160090387-A1 CALCIUM CHANNEL AGONISTS CACNA1E, CACNA1C, CACNA1S CDK1 2530/4885ADORA1 381/4885TMIGD3 2058/4885
US-10174031-B2 Calcium channel agonists CACNA1E, CACNA1C, CACNA1S CDK1 2530/4885ADORA1 381/4885TMIGD3 2058/4885
US-10752629-B2 Calcium channel agonists CACNA1E, CACNA1C, CACNA1S CDK1 2530/4885ADORA1 381/4885TMIGD3 2058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.